Poster preview
ePoster
ADAM10-TARGETING MICRORNAS IN SERUM AS PERIPHERAL BIOMARKERS LINKING ALZHEIMER’S DISEASE AND TYPE 2 DIABETES
Patricia Morallesand 7 co-authors
University of Barcelona, Faculty of Nursing
FENS Forum 2026 (2026)
Barcelona, Spain
Board PS05-09AM-081
Presentation
Date TBA
Board: PS05-09AM-081
Event Information
Poster Board
PS05-09AM-081
Poster
View posterAbstract
The aim of this study was to investigate circulating microRNAs (miRNAs) targeting ADAM10, the main α-secretase involved in non-amyloidogenic amyloid precursor protein processing, as potential blood-based biomarkers for Alzheimer´s disease (AD) and AD associated with Type 2 Diabetes Mellitus (T2D). The project was submitted and approved by the bioethics committee. Candidate ADAM10-targeting miRNAs were identified through an integrated bioinformatic pipeline using miRTargetLink, miEAA and miRNet, followed by experimental validation in serum samples from ACE-Barcelona of MCI (mild cognitive impairment) (A-T-N-) (n = 20); MCI+T2D (A-T-N-) (n = 13); AD (A+T+N+) (n = 20) and combined AD and T2D (A+T+N+) (n = 20). Serum miRNA were extracted using the miRNeasy Serum/Plasma Kit and quantified by RT-qPCR, using TaqMan MicroRNA assays. Relative quantification was calculated using the ΔΔCt method with miR-16 as endogenous reference. Several miRNAs showed significant differences between groups, with miR-92, miR-103, miR-19 and miR-221 significantly upregulated in AD compared with controls. Notably, miR-103 and miR-19 exhibited a progressive increase from controls to AD, reaching the highest levels in AD with T2D, indicating sensitivity to combined neurodegenerative and metabolic burden. In contrast, other ADAM10-targeting miRNAs displayed limited discriminatory value. These results demonstrate that a subset of circulating ADAM10-targeting miRNAs can discriminate AD from MCI and reflect disease severity in the presence of T2D. We conclude that these miRNAs represent promising peripheral biomarkers for AD diagnosis and condition stratification and may support the development of accessible, low-cost biomarker-based diagnostic platforms.
Recommended posters
SYNAPTIC MIRNA DYSREGULATION IN ALZHEIMER’S DISEASE HUMAN TISSUE
Laia Lidón, Xuanyang Bai, Alba Fernández Sanromà, Raúl Núñez Llaves, Alba Cervantes González, Danna Perlaza, Maria Dolores Capilla, Natalia Valle Tamayo, Érika Sánchez Aced, Borja Moya Llamas, Aleyda Benítez Amaro, Esther Álvarez Sánchez, Laia Muñoz, Joaquim Aumatell, Laura Cervera Carles, Sònia Sirisi, Oriol Dols Icardo, Alberto Lleó, Olivia Belbin
MIR-19A-3P INHIBITION IMPROVES MEMORY AND SYNAPTIC FUNCTION IN ALZHEIMER’S DISEASE
Mireia Millet Sigalat, Leila Driouech, Judit Chamorro-Duran, Marina Carrasco, Ester Verdaguer, Carme Auladell, Antoni Camins, Jordi Olloquequi, Miren Ettcheto
SMALL FRAGMENTS OF AB FOR THE DIAGNOSIS OF ALZHEIMER´S DISEASE AND PREDICTION OF ARIA IN IMMUNOTHERAPY
Fanni Újvárosi, Sara Tran, Jie Gao, Line Amundsen, Emilie Gasparini, Brage Milch Johannesen, Ingrid Kjønstad, Vebjørn Andersson, Ira R. J. Hebold Haraldsen, Erik Christensen, Maria J. Lagartos-Donate
PLASMA PROTEOLYTIC IMBALANCE AS A SIGNATURE TO DIFFERENTIATE ALZHEIMER’S DISEASE FROM FRONTOTEMPORAL AND LEWY BODY DEMENTIAS
Miren Ettcheto, Patricia Regina Manzine, Marina Mantellatto Grigoli, Suelen Santos Alves, Norberto Garcia-Cairasco, Karina Braga Gomes, Paulo Caramelli, Vitor Tumas, Antoni Camins, Fabiana de Souza Orlandi, Marcia Regina Cominetti
DEVELOPMENT OF TOOLS TO MODULATE ADAM10 TRAFFICKING IN ALZHEIMER’S DISEASE
Jasmine Molaschi, Annarita D'Urso, Lorenzo Targa, Silvia Pelucchi, Ramona Stringhi, Giovanni Di Muccio, Alice Romagnoli, Anna La Teana, Francesca Vasile, Laura Belvisi, Monica Di Luca, Elena Marcello
AUTOPHAGY-LYSOSOMAL PATHWAY PROTEINS IN DERMAL FIBROBLASTS AS POTENTIAL PERIPHERAL BIOMARKERS FOR ALZHEIMER'S DISEASE DIAGNOSIS
Myung Shin Lee, Sang Joon Son, Juyeong Kim, Seungbeom Go, Chang Hyung Hong, Hyun Woong Roh, Jaerak Chang